L. Mary Smith has sold SWTX and made no open-market buys since Jan 2021
Chief Development Officer at Springworks Therapeutics, Inc.
SEC CIK 0001787013 · Filings on SEC.gov ↗
$0Bought
$2.8MSold
NoneLast buy
Every filing
4 filings since Jan 2021, newest first
SWTXSell
Springworks Therapeutics, Inc.
Chief Development Officer
$560K−6.0%Oct 13
SWTXSell
Springworks Therapeutics, Inc.
Chief Development Officer
$809K−6.0%Jul 14
SWTXSell
Springworks Therapeutics, Inc.
Chief Development Officer
$681K−6.0%Apr 13
SWTXSell
Springworks Therapeutics, Inc.
Chief Development Officer
$787K−6.0%Jan 21
Filings come from SEC EDGAR. Not investment advice.